Will Dendreon Plunge Again?
In this video, health care analysts David Williamson and Max Macaluso discuss Dendreon's upcoming third-quarter earnings. David highlights what investors need to look for in the company's press release -- and more importantly, the conference call. Watch and be prepared for Friday's big news.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Will Dendreon Plunge Again? originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.